Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Trading Up 4.3%

Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) shares were up 4.3% during trading on Wednesday . The stock traded as high as $0.24 and last traded at $0.24, approximately 14,910 shares were traded during trading. A decline of 99% from the average daily volume of 1,060,599 shares. The stock had previously closed at $0.23.

Several research analysts have recently issued reports on the company. Zacks Investment Research cut Actinium Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, June 4th. William Blair assumed coverage on Actinium Pharmaceuticals in a research report on Thursday, August 8th. They set an “outperform” rating for the company. Finally, Maxim Group set a $3.00 price objective on Actinium Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, June 4th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $3.56.

An institutional investor recently raised its position in Actinium Pharmaceuticals stock. Sio Capital Management LLC raised its holdings in shares of Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) by 1,352.4% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,935,250 shares of the biotechnology company’s stock after acquiring an additional 4,595,454 shares during the quarter. Sio Capital Management LLC owned approximately 3.05% of Actinium Pharmaceuticals worth $1,214,000 as of its most recent filing with the SEC.

Actinium Pharmaceuticals Company Profile (NYSEAMERICAN:ATNM)

Actinium Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, Iomab-B that is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant.

Further Reading: After-Hours Trading

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with's FREE daily email newsletter.